Introduction
Cholangiocarcinoma represents a challenging primary malignant tumor with no effective medical therapy and a poor prognosis. The etiology of cholangiocarcinoma remains unknown. In our previous investigations, we have demonstrated that human cholangiocarcinoma cell lines heterogeneously express Fas antigen at the cell surface. We have isolated two subpopulations based on their Fas levels: one with low Fas expression (Fas L ) and the other with high Fas expression (Fas H ) (1, 2) . The Fas L cells, but not Fas H cells, are resistant to apoptosis induced by Fas activating antibody and by other apoptotic stimuli (3) (4) (5) and are capable of producing tumors when subcutaneously injected into nude mice (2, 5) . These results suggest that the down-regulation of Fas expression and resistance to Fas-activated apoptosis might play a crucial role in the tumorigenesis of cholangiocarcinoma.
Although decreased Fas expression in tumors is frequently associated with enhanced malignant growth or metastasis (6, 7) , a decrease in Fas expression alone is unlikely to be entirely responsible for the enhanced neoplastic growth and metastasis (8) . Tumor cells must require additional molecular mechanisms to render them resistant to host immune attack (9) . Malignant cells have several mechanisms to escape immune surveillance including expression of low levels of target tumor antigens (10) . Expression of FasL on tumor cells is also one of the mechanisms by which malignant cells escape the host immune attack. It has been reported that many carcinomas aberrantly express FasL, whereas the parallel normal tissues do not (11) (12) (13) . Expression of FasL by malignant tumors may counteract the host's anti-tumor immunity and favor tumor growth by killing infiltrating T lymphocytes through Fas-FasL interaction (14) (15) (16) . When FasL-positive melanoma cells were injected into mice, tumors developed more rapidly in wild-type mice compared with Fas deficient lpr mutants, suggesting that functional FasL on tumors may be involved in the destruction of immune cells and in maintaining a state of tumor immune privilege (17) .
The hypothesis that FasL is important for tumor growth and immune privilege has been challenged (18, 19) . Tumor cells transfected with the gene encoding FasL induced rapid tumor regression rather than fostering tumor development. However, the level of Fas expression by these transfected tumor cells was not indicated (14, 20, 21) . We hypothesized that simultaneously decreased Fas expression and increased FasL expression in tumor cells are required for tumor growth or metastasis. Reciprocal expression of Fas and FasL in tumors has been observed in previous studies (22, 23 
Materials and methods
Cell culture. Human cholangiocarcinoma cells (SK-ChA-1) were generously provided by Dr A. Knuth (Ludwig Institute for Cancer Research, London, UK) and their growth conditions were described previously (1,2). Cells were subcloned by flow cytometric sorting into two subpopulations, those expressing low amounts of Fas (Fas L ) and those expressing high amounts of Fas (Fas H ), as previously reported (1, 2) .
Isolation of RNA and quantitative real-time RT-PCR.
Total RNA was isolated with TRIzol reagent (Invitrogen, Palo Alto, CA) according to the manufacturer's protocol. Firststrand cDNA was synthesized by annealing RNA (1 μg) with 250 ng of random primers by heating at 70˚C for 2 min. After denaturing, samples were incubated with reverse transcriptase, 10 mM dithiothreitol, RNasin (Promega, Madison, WI) and 0.5 mM dNTPs in a total volume of 20 μl for 1 h at 42˚C. The reaction mixture was diluted to a final volume of 100 μl and heat-inactivated at 95˚C for 5 min.
Real-time RT-PCR was performed on an ABI GeneAmp 5700 sequence detection system using SYBR-Green labeling primers (Applied Biosystems, Foster City, CA). In the total volume of 25 μl reaction mixture, 22.5 μl master mix, 2.5 μl cDNA (corresponding to 25 ng of total RNA), and 6 μM of forward and reverse primers were added. The reaction mixture was heated for 5 min at 95˚C and then 40 PCR cycles consisting of 15 sec at 95˚C and 60 sec at 60˚C were performed. The product accumulation was monitored by SYBR-Green fluorescence (24) . The sequences of primers used for realtime RT-PCR were as follows: GAPDH 5'-GATTCCACCC ATGGGAATT-3' (forward), 5'-GGGTGGTGGAAGATGGT GAT-3' (reverse); Fas 5'-ACTTCGGAGGATTGCTCAACA-3' (forward), 5'-ACTTCGGAGGATTGCTCAACA-3' (reverse); and FasL 5'-AAAGTGGCCGATTTAACAGGC-3' (forward), 5'-GCAACAGACGTAAGAACCAGAGG-3' (reverse). The relative gene expression levels were determined from the standard curve and were calculated using software provided by the manufacturer (Applied Biosystems). Isolation of FasL from cell culture supernatants. FasL from tumor cell supernatants was isolated as described previously (9, 25, 26) . Briefly, cell culture supernatants collected from the Fas H and Fas L tumor cells were centrifuged twice at 200 x g for 20 min at 4˚C followed by ultracentrifuging at 47,000 x g at 4˚C for 3 h (Beckman, T50). The microvesicle pellet was washed with PBS and then treated with or without 1% Triton X100 at 4˚C for 30 min. The microvesicle supernatant was collected and stored at -80˚C after centrifuging at 23,000 x g at 4˚C for 1 h.
Assessment of released FasL bioactivity.
The function of FasL released from tumor cells was determined as described previously (26) . Jurkat cells were cultured with the indicated volumes of the prepared microvesicle supernatants overnight. The medium and Fas activating antibody (50 ng/ml) were used as a negative and a positive control. After incubation, apoptosis was determined by an Annexin V assay as per the manufacturer's instructions.
Electrophoretic mobility shift analysis (EMSA).
Nuclear extracts were prepared as described previously (27) . The double-stranded oligonucleotides containing the consensus NF-κB binding site in the Fas and FasL promoters were labeled by a kinase reaction with T4 polynucleotide kinase and [γ-32 P]-ATP. EMSA was performed using 2 ng of labeled doublestrand oligonucleotides containing an NF-κB consensus binding motif (10,000 cpm, Promega, Madison, WI), and 5 μg of nuclear extract according to Promega's gel shift assay core system.
Plasmids, transient transfection and luciferase assay. PCRamplified fragments of the Fas promoter (1.8 kb) and FasL promoter (1.7 kb) were subcloned into KPNI and HindIII restriction sites of the luciferase reporter vector pGL3-basic (Promega). The activities of the Fas and FasL promoters in the Fas H and Fas L cells were determined by a dual-luciferase reporter assay system (Invitrogen, Carlsbad, CA). Luciferase reporter pGL3-basic vectors containing the Fas promoter or the FasL promoter were transfected into the Fas H and Fas L cells using Lipofectamine and Plus™ reagent per the manufacturer's instructions. A luciferase reporter plasmid containing RenillaLuciferase driven by an SV40 promoter (pRF-SV40) was used as an internal control for transfection efficiency. Two days after transfection, the luciferase activity in 50 μl of cell lysate was assayed and normalized to Renilla-Luciferase activity for transfection efficiencies.
Immunohistochemical staining of Fas and FasL.
Immunohistochemical staining of Fas and FasL was performed in tumor specimens produced by subcutaneous injection of the Fas L cells into nude mice as previously described (1, 2) . Briefly, tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 6-μm sections (15) . After dewaxing and rehydration, the slides were incubated with 0.5% hydrogen peroxide in water for 30 min to block endogenous peroxidase activity and 5% BSA blocking buffer for 30 min to reduce nonspecific binding. Expression of Fas and FasL was determined using anti-human monoclonal antibodies (BD Biosciences, Palo Alto, CA). The secondary horseradish peroxidase (HRP)-conjugated goat anti-mouse serum (Dako) was used at 1/200 for 30 min. The color reaction was developed using 3,3'-diaminobenzidine tetrahydrochloride (DAB). Negative control slides were prepared without the primary antibody but retaining all of the other steps. (Fig. 1A) .
Results

Reciprocal expression of Fas and FasL proteins and transcripts in the Fas
We previously demonstrated that the Fas L , but not the Fas H , cells produced tumors following subcutaneous injection into nude mice (2) . To confirm the reciprocal expression of Fas and FasL in engraftments, we determined the expression of Fas and FasL in formalin-fixed paraffin embedded engraftments, produced by the injection of Fas L cells into the flanks of nude mice (1,2). Tumor cells were stained intensely by FasL antibody as indicated by the intense brown staining (Fig. 1B, FasL panel) . As expected, Fas expression in the tumor engraftments was not detectable (Fig. 1B, Fas panel) . The negative control was incubated with the secondary antibody only (Fig. 1B, control panel) .
To (Fig. 1D) .
The function of surface FasL in the Fas
H and Fas L cells. To assess whether the higher levels of FasL in the Fas L cells are capable of killing Fas-bearing cells, a cytotoxicity assay using 51 Cr-labeled target cells was performed. Fig. 2 51 Cr-labeled A20 cells (T) at the indicated ratio of E/T for 12 h. The released radioactivity in the supernatants was measured. The Y-axis represents the percentage of specific toxicity calculated by the formula given in the Materials and methods. The X-axis represents the ratio of (E/T). The results are shown as the mean ± SE from three independent experiments. reported that the potential for metastasis of osteosarcoma is inversely correlated with Fas expression (7) . In cholangiocarcinoma, down-regulation of Fas significantly correlated with histological de-differentiation, vascular invasion, and the size of the tumor (22) . However, dysregulation of Fas expression alone was reported to be insufficient to promote tumor progression, because blocking Fas expression in the Fas-expressing cells did not reduce tumor progression (8) , implying that other genes may also contribute. Aberrant FasL expression in the Fas L cells may contribute to its tumorigenic capacity.
The role of FasL expression in tumorigenesis remains controversial. For example, FasL-expressing carcinomas had significantly higher potential of lymph node and distant metastases than carcinomas that did not express FasL, supporting the hypothesis that aberrant FasL expression enhances tumor growth and metastasis (34) . In contrast to this hypothesis, suppressing FasL expression in melanoma cells enhanced lung metastasis (35) . In addition, other controversies concern the specificity of the reagents used for detection of FasL (antibodies, PCR assay, primers), the presence or absence of tumor-specific T lymphocytes infiltrating cancer lesions and whether or not tumors regress following delivery of FasLexpressing T cells into mice (19, 36) . Using heterogeneous cell lines may also cause varying results. The use of homogenous cloned cells in our system avoids these controversial factors providing an opportunity to simultaneously determine the roles of Fas and FasL in tumorigenesis. Our results indicate that increased FasL, either on the membrane of or released from the Fas L cells, is capable of inducing apoptosis of Jurkat lymphocytes (Fig. 3) suggesting the function of FasL on tumor cells in protecting from immune attack by the host. It has been reported that the prognosis of patients with malignant tumors is dependent on the FasL expression of their tumors and the concomitant presence of apoptotic T cells in tumor lesions. Thus, the Fas L cells not only have an acquired defensive mechanism (Fas resistance), but also provide an offensive mechanism (counterattack) through expressing FasL (37) .
In tumors, FasL has been demonstrated to have two forms: surface and soluble. The surface FasL is responsible for transduction of the Fas apoptotic signal after cell-cell contact (38) . The soluble FasL (sFasL) released from tumor cells by a proteolytic metalloproteinase is unable to transduce the apoptotic death signal and, therefore, presumably suppresses Fas-mediated apoptosis as a decoy receptor for Fas (39 (Fig. 4) . This suggests that some common transcription factors may participate in the reciprocal regulation of Fas and FasL expression.
The transcriptional machinery regulating the expression of Fas and FasL is not yet fully known. Several transcription factors have been identified that regulate Fas and FasL expression. Watabe et al reported that transcription factor, NF-κB, down-regulates Fas activation and inhibits Fasmediated apoptosis (42), whereas Lu et al reported that NF-κB up-regulates FasL expression and activates FasL-mediated apoptosis (43) . Several studies identified the location of NF-κB binding motifs in the Fas (44, 45) and FasL promoters (46, 47) (Fig. 4) . In this study, we simultaneously analyzed the effects of NF-κB on Fas and FasL and found that the Fas L cells have higher activity of NF-κB compared to the Fas H cells (Fig. 5 ). These observations confirm that NF-κB down-regulates Fas and up-regulates FasL, simultaneously. Furthermore, inhibiting this elevated NF-κB activity in the Fas L cells by APDC, an NF-κB inhibitor, significantly increased Fas and decreased FasL expression. Lu et al demonstrated that FasL-induced apoptosis was increased and TNF-α expression decreased by a specific NF-κB inhibitor or dominant expression of IκB subunit (43) .
In conclusion, human cholangiocarcinoma cells reciprocally express functional Fas and FasL, which may be caused by the inverse activity of the Fas and FasL promoter regulated by NF-κB. Reciprocal expression of Fas and FasL in human cholangiocarcinoma may contribute to the survival of tumor cells, the failure of immune surveillance, and growth and metastasis of tumors. Regulating a single mechanism responsible for this reciprocal expression may provide opportunities for new therapies.
